Randomized Phase II Cancer Clinical Trials to Validate Predictive Biomarkers
Our method provides a practical approach to validating predictive biomarkers in phase II cancer trials. The simulations demonstrate robust performance for both interaction models, offering guidance for the sample size selection and analysis strategy in biomarker-stratified trials.
Authors
- Sin‐Ho Jung (ORCID: https://orcid.org/0000-0002-1473-7236)
- Jong‐Mu Sun (ORCID: https://orcid.org/0000-0001-9683-4111)
- Myung‐Ju Ahn (ORCID: https://orcid.org/0000-0002-5740-9654)
- Baoshan Zhang (ORCID: https://orcid.org/0000-0003-0925-8713)
Institutions
- Duke University (US)
- Samsung Medical Center (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Biomedicines
- Published
- 2024-09-26
- DOI
- https://doi.org/10.3390/biomedicines12102185
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00